These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 17975003)
41. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer. Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215 [TBL] [Abstract][Full Text] [Related]
42. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells. Ogba N; Manning NG; Bliesner BS; Ambler SK; Haughian JM; Pinto MP; Jedlicka P; Joensuu K; Heikkilä P; Horwitz KB Breast Cancer Res; 2014 Dec; 16(6):489. PubMed ID: 25475897 [TBL] [Abstract][Full Text] [Related]
44. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Bird PA; Hill AG; Houssami N Ann Surg Oncol; 2008 Jul; 15(7):1983-8. PubMed ID: 18408976 [TBL] [Abstract][Full Text] [Related]
45. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. Baselga J; Zambetti M; Llombart-Cussac A; Manikhas G; Kubista E; Steger GG; Makhson A; Tjulandin S; Ludwig H; Verrill M; Ciruelos E; Egyhazi S; Xu LA; Zerba KE; Lee H; Clark E; Galbraith S J Clin Oncol; 2009 Feb; 27(4):526-34. PubMed ID: 19075286 [TBL] [Abstract][Full Text] [Related]
46. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas. Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613 [TBL] [Abstract][Full Text] [Related]
47. Silencing of LRRC49 and THAP10 genes by bidirectional promoter hypermethylation is a frequent event in breast cancer. De Souza Santos E; De Bessa SA; Netto MM; Nagai MA Int J Oncol; 2008 Jul; 33(1):25-31. PubMed ID: 18575747 [TBL] [Abstract][Full Text] [Related]
48. Steroid receptors and their role in the biology and control of breast cancer growth. Cordera F; Jordan VC Semin Oncol; 2006 Dec; 33(6):631-41. PubMed ID: 17145341 [TBL] [Abstract][Full Text] [Related]
49. Role of interleukin-8 in the progression of estrogen receptor-negative breast cancer. Yao C; Lin Y; Ye CS; Bi J; Zhu YF; Wang SM Chin Med J (Engl); 2007 Oct; 120(20):1766-72. PubMed ID: 18028768 [TBL] [Abstract][Full Text] [Related]
50. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J; J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604 [TBL] [Abstract][Full Text] [Related]
51. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Doane AS; Danso M; Lal P; Donaton M; Zhang L; Hudis C; Gerald WL Oncogene; 2006 Jun; 25(28):3994-4008. PubMed ID: 16491124 [TBL] [Abstract][Full Text] [Related]
52. [Comparative evaluation of proliferative activity of breast tumors of different estrogen-progesterone receptor status]. Ellinidi VN; Anikeeva NV; Goncharova OA; Krasnozhon DA Vopr Onkol; 2005; 51(2):197-9. PubMed ID: 16223000 [TBL] [Abstract][Full Text] [Related]
53. [Growth dynamics of breast cancer. Comparison of cytohistologic parameters of the primary tumor, lymph node metastases and recurrent tumors]. Stosiek U; Wolfmüller H Zentralbl Gynakol; 1986; 108(11):665-9. PubMed ID: 3751375 [TBL] [Abstract][Full Text] [Related]
54. Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. Harvell DM; Richer JK; Allred DC; Sartorius CA; Horwitz KB Endocrinology; 2006 Feb; 147(2):700-13. PubMed ID: 16239301 [TBL] [Abstract][Full Text] [Related]
55. Metastatic breast cancer from an occult primary provisionally identified by steroid receptor content and two-dimensional protein electrophoresis: some problems associated with the use of the latter technique. Anderson KM; Bonomi P Clin Physiol Biochem; 1985; 3(5):265-70. PubMed ID: 4053492 [TBL] [Abstract][Full Text] [Related]
56. Comparison Between HER2, Estrogen Receptors and Progesterone Receptors in Primary Breast Carcinomas and Matched Lymph Node Metastases. Desouki MM; Atta IS; Wolff DJ; Self SE Turk Patoloji Derg; 2016; 32(3):178-85. PubMed ID: 27562392 [TBL] [Abstract][Full Text] [Related]
57. Estrogen or antiprogestin treatment induces complete regression of pulmonary and axillary metastases in an experimental model of breast cancer progression. Vanzulli SI; Soldati R; Meiss R; Colombo L; Molinolo AA; Lanari C Carcinogenesis; 2005 Jun; 26(6):1055-63. PubMed ID: 15774491 [TBL] [Abstract][Full Text] [Related]
58. Breast cancer metastases are molecularly distinct from their primary tumors. Vecchi M; Confalonieri S; Nuciforo P; Viganò MA; Capra M; Bianchi M; Nicosia D; Bianchi F; Galimberti V; Viale G; Palermo G; Riccardi A; Campanini R; Daidone MG; Pierotti MA; Pece S; Di Fiore PP Oncogene; 2008 Apr; 27(15):2148-58. PubMed ID: 17952122 [TBL] [Abstract][Full Text] [Related]
59. Genomic instability and the development of metastatic lymph node tumors. Callaghan KA; Becker TE; Ellsworth DL; Hooke JA; Ellsworth RE; Shriver CD Ann Surg Oncol; 2007 Nov; 14(11):3125-32. PubMed ID: 17653592 [TBL] [Abstract][Full Text] [Related]